Charles River Laboratories International, Inc. (CRL) stock
CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30207% above fair value
$314.32−13.61 (-4.15%)
Close on Nov 20, 2026Market cap $15.01BP/E –Yield –
Charles River Laboratories International free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Charles River Laboratories International's free cash flow for the twelve months ending Jun 27, 2026 was $370.61M, down 35.9% year over year. For fiscal 2025 it was $518.49M, up 3.4% from the year before. Over ten years it grew 7.8% a year on average. The highest annual figure on record is $532.03M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $518.49M | +3.4% |
| FY2024 | Dec 28, 2024 | $501.61M | +37.3% |
| FY2023 | Dec 30, 2023 | $365.37M | +23.9% |
| FY2022 | Dec 31, 2022 | $294.91M | -44.6% |
| FY2021 | Dec 25, 2021 | $532.03M | +40.0% |
| FY2020 | Dec 26, 2020 | $380.02M | +11.6% |
| FY2019 | Dec 28, 2019 | $340.42M | +13.1% |
| FY2018 | Dec 29, 2018 | $301.09M | +27.8% |
| FY2017 | Dec 30, 2017 | $235.64M | -9.9% |
| FY2016 | Dec 31, 2016 | $261.61M | +7.4% |
| FY2015 | Dec 26, 2015 | $243.58M | +24.8% |
| FY2014 | Dec 27, 2014 | $195.21M | +14.9% |
| FY2013 | Dec 28, 2013 | $169.89M | +5.9% |
| FY2012 | Dec 29, 2012 | $160.47M | +1.8% |
| FY2011 | Dec 31, 2011 | $157.70M | +25.8% |
| FY2010 | Dec 25, 2010 | $125.38M | -7.6% |
| FY2009 | Dec 26, 2009 | $135.72M | +76.4% |
| FY2008 | Dec 27, 2008 | $76.92M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 27, 2026 | $148.62M | -12.2% |
| Q1 FY2026 | Mar 28, 2026 | -$14.83M | -113.2% |
| Q4 FY2025 | Dec 27, 2025 | $58.57M | -30.1% |
| Q3 FY2025 | Sep 27, 2025 | $178.25M | -16.3% |
| Q2 FY2025 | Jun 28, 2025 | $169.31M | +9.9% |
| Q1 FY2025 | Mar 29, 2025 | $112.37M | +121.5% |
| Q4 FY2024 | Dec 28, 2024 | $83.75M | -41.3% |
| Q3 FY2024 | Sep 28, 2024 | $213.07M | +52.7% |
| Q2 FY2024 | Jun 29, 2024 | $154.05M | +90.8% |
| Q1 FY2024 | Mar 30, 2024 | $50.74M | +1923.3% |
| Q4 FY2023 | Dec 30, 2023 | $142.62M | -2.1% |
| Q3 FY2023 | Sep 30, 2023 | $139.50M | +131.0% |
| Q2 FY2023 | Jul 1, 2023 | $80.74M | +21.2% |
| Q1 FY2023 | Apr 1, 2023 | $2.51M | -88.7% |
| Q4 FY2022 | Dec 31, 2022 | $145.73M | +11.7% |
| Q3 FY2022 | Sep 24, 2022 | $60.39M | -49.3% |
| Q2 FY2022 | Jun 25, 2022 | $66.62M | -52.5% |
| Q1 FY2022 | Mar 26, 2022 | $22.17M | -84.4% |
| Q4 FY2021 | Dec 25, 2021 | $130.48M | +158.3% |
| Q3 FY2021 | Sep 25, 2021 | $119.19M | -21.1% |
| Q2 FY2021 | Jun 26, 2021 | $140.16M | +3.4% |
| Q1 FY2021 | Mar 27, 2021 | $142.20M | +231.7% |
| Q4 FY2020 | Dec 26, 2020 | $50.53M | -56.8% |
| Q3 FY2020 | Sep 26, 2020 | $151.12M | +25.2% |
| Q2 FY2020 | Jun 27, 2020 | $135.51M | +29.3% |
| Q1 FY2020 | Mar 28, 2020 | $42.87M | – |
| Q4 FY2019 | Dec 28, 2019 | $116.84M | +63.9% |
| Q3 FY2019 | Sep 28, 2019 | $120.68M | +27.3% |
| Q2 FY2019 | Jun 29, 2019 | $104.77M | +2.1% |
| Q1 FY2019 | Mar 30, 2019 | -$1.87M | -105.8% |
| Q4 FY2018 | Dec 29, 2018 | $71.30M | -25.5% |
| Q3 FY2018 | Sep 29, 2018 | $94.81M | +153.0% |
| Q2 FY2018 | Jun 30, 2018 | $102.66M | +21.7% |
| Q1 FY2018 | Mar 31, 2018 | $32.33M | +78.5% |
| Q4 FY2017 | Dec 30, 2017 | $95.73M | +3.0% |
| Q3 FY2017 | Sep 30, 2017 | $37.47M | -40.3% |
| Q2 FY2017 | Jul 1, 2017 | $84.33M | – |
| Q1 FY2017 | Apr 1, 2017 | $18.11M | – |
| Q4 FY2016 | Dec 31, 2016 | $92.97M | – |
| Q3 FY2016 | Sep 24, 2016 | $62.73M | – |
See a number that looks wrong?